# Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)

> **NCT02926456** · — · COMPLETED · sponsor: **Janssen-Cilag S.p.A.** · enrollment: 337 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02926456
- **Lead sponsor:** Janssen-Cilag S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-22
- **Primary completion:** 2018-02-14
- **Final completion:** 2018-02-14
- **Target enrollment:** 337 (ACTUAL)
- **Last updated:** 2018-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926456, "Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02926456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*